[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Shigeto M, Cha CY, Rorsman P, Kaku K
Dozens of diet, drug and exercise regimens didn't work, and advice from doctors was always the same: Eat less
Recent advances in peptide-based therapies for obesity and type 2 diabetes
References Batterham, R
If ones like that are already pivoting, then it tells us that in our mid-market space, we really need to be doing the same, he said